$VTGN News

Last published 3d ago

3d agoVTGNVistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety DisorderGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced a
3d agoVTGNVistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety DisorderGlobeNewswireConstructive feedback from FDA clarifies potential Phase 3 development path forward
3w agoVTGNVistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development ProgramsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced its
2mo agoVTGNVistagen to Present at Psych Congress 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class
3mo agoVTGNVistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateGlobeNewswireExploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current
3mo agoVTGNVistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderGlobeNewswireRepeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified
3mo agoSRXH VTGNSRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)GlobeNewswireNORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company", or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through
3mo agoVTGN DRUGVistagen Appoints Douglas J. Williamson to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and
4mo agoVTGNVistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness WireFasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in
5mo agoVTGNVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
5mo agoVTGNKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ:...
5mo agoVTGNVistagen to Participate in Jefferies 2026 Global Healthcare ConferenceBusiness WireVistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today
5mo agoVTGNVistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical OfficerBusiness WireDr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to
6mo agoVTGNVistagen to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceBusiness WireVistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today
6mo agoVTGNVistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness WireFasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months Clinically relevant improvement in
6mo agoVTGNVistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety DisorderBusiness WireTopline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain
6mo agoVTGNKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) breached their
6mo agoVTGNVistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
8mo agoVTGNVistagen to Participate in Upcoming Investor ConferencesBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
8mo agoVTGNVistagen to Participate in the 46th Annual TD Cowen Healthcare ConferenceBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
9mo agoVTGNVistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026Business WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
9mo agoVTGNInvestors in Vistagen Therapeutics, Inc. Should Contact The Gross Law Firm Before March 16, 2026 to Discuss Your Rights - VTGNPR NewswireThe Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of...
9mo agoVTGNINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. ("Vistagen" or...
9mo agoVTGNUPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
9mo agoVTGNVistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before March 16, 2026 to Discuss Your Rights – VTGNGlobeNewswireNEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ:VTGN). Shareholders who purchased shares of VTGN during the class
11mo agoVTGNVistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness WireStudy did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo Favorable safety and tolerability data were consistent with
11mo agoAZN SENS VTGNVistagen Appoints Nick Tressler as Chief Financial OfficerBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
11mo agoVTGNVistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual MeetingBusiness WireResearch supports the product candidate's non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with
12mo agoVTGNVistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate UpdateBusiness WirePALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end Vistagen (NASDAQ:VTGN), a late
1y agoVTGNVistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025Business WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
1y agoVTGNVistagen to Participate in Stifel Healthcare Conference 2025Business WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
1y agoVTGNVistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety DisorderBusiness WireTopline results for the trial are expected by year end Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a
1y agoVTGNVistagen Appoints Paul Edick to its Board of DirectorsBusiness WireMr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with
1y agoVTGNVistagen to Present at The Menopause Society 2025 Annual MeetingBusiness WirePosters Highlight New Insights into PH80's Effects on Brain and Autonomic Activity Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to
1y agoVTGNVistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy SummitBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
1y agoVTGNVistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptEarnings Call Transcripts
1y agoVTGNVistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate UpdateBusiness WireTopline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of
1y agoVTGNVistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025Business WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
1y agoVTGNVistagen to Present at the BTIG Virtual Biotechnology ConferenceBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
1y agoVTGNVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipBusiness WireCompany is awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health and certified as a Great Place to Work® Recognition underscores commitment to mission-driven culture and exceptional
1y agoVTGNVistagen Appoints Elissa Cote as Chief Corporate Development OfficerBusiness WireAccomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's
1y agoVTGNVistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateBusiness WireTopline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half
1y agoVTGNVistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025Business WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
1y agoVTGNVistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This YearBusiness WireCompany's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry
1y agoVTGNVistagen to Present at the Jefferies 2025 Global Life Sciences Conference New YorkBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
1y agoVTGNVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceBusiness WirePosters Highlight New Insights into Social Anxiety Disorder and the Novel Mechanism of Action of Itruvone to Treat Major Depressive Disorder Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering
1y agoVTGNVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceBusiness WireNew Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in
1y agoVTGNVistagen to Present at the 2025 Anxiety and Depression Association ConferenceBusiness WirePosters Highlight New Insights into Social Anxiety Disorder Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a
1y agoVTGNVistagen to Participate in Stifel 2025 Virtual CNS ForumBusiness WireVistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
1y agoVTGNVistagen to Participate in the 45th Annual TD Cowen Healthcare ConferenceBusiness WireVistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,